These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 35461372

  • 1. Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction.
    Vadla GP, Daghat B, Patterson N, Ahmad V, Perez G, Garcia A, Manjunath Y, Kaifi JT, Li G, Chabu CY.
    Sci Rep; 2022 Apr 23; 12(1):6693. PubMed ID: 35461372
    [Abstract] [Full Text] [Related]

  • 2. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
    Li XF, Shen WZ, Jin X, Ren P, Zhang J.
    Sci Rep; 2020 Jul 08; 10(1):11236. PubMed ID: 32641854
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T, Azuma K, Shimokawa M, Takeda M, Ishii H, Kato T, Saito H, Daga H, Tsuboguchi Y, Okamoto I, Otsubo K, Akamatsu H, Teraoka S, Takahashi T, Ono A, Ohira T, Yokoyama T, Sakai K, Yamamoto N, Nishio K, Nakagawa K.
    Cancer; 2020 Jan 01; 126(9):1940-1948. PubMed ID: 32022929
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients.
    Janpipatkul K, Trachu N, Watcharenwong P, Panvongsa W, Worakitchanon W, Metheetrairut C, Oranratnachai S, Reungwetwattana T, Chairoungdua A.
    Cancer Biomark; 2021 Jan 01; 31(3):281-294. PubMed ID: 33896827
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells.
    Liu S, Jiang Z, Xiao P, Li X, Chen Y, Tang H, Chai Y, Liu Y, Zhu Z, Xie Q, He W, Ma Y, Jin L, Feng W.
    Cancer Sci; 2022 Jan 01; 113(1):79-90. PubMed ID: 34706132
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
    Dal Maso A, Lorenzi M, Ferro A, Pilotto S, Cecere F, Follador A, Polo V, Del Conte A, Sartori G, Giavarra M, Scattolin D, Indraccolo S, Frega S, De Maglio G, Menis J, Bonanno L, Calabrese F, Guarneri V, Conte P, Pasello G.
    Future Oncol; 2021 Jul 01; 17(19):2513-2527. PubMed ID: 33988036
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC).
    Abdipourbozorgbaghi M, Vancura A, Radpour R, Haefliger S.
    Br J Cancer; 2024 Nov 01; 131(8):1350-1362. PubMed ID: 39215192
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.
    Genova C, Marconi S, Chiorino G, Guana F, Ostano P, Santamaria S, Rossi G, Vanni I, Longo L, Tagliamento M, Zullo L, Dal Bello MG, Dellepiane C, Alama A, Rijavec E, Ludovini V, Barletta G, Passiglia F, Metro G, Baglivo S, Chiari R, Rivoltini L, Biello F, Baraibar I, Gil-Bazo I, Novello S, Grossi F, Coco S.
    Clin Exp Med; 2024 Aug 06; 24(1):182. PubMed ID: 39105937
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
    Akazawa Y, Saito Y, Yoshikawa T, Saito K, Nosaka K, Shimomura M, Mizuno S, Nakamoto Y, Nakatsura T.
    Cancer Sci; 2020 Aug 06; 111(8):2736-2746. PubMed ID: 32391625
    [Abstract] [Full Text] [Related]

  • 19. Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib.
    Kuo CS, Huang CH, Liu CY, Pavlidis S, Ko HW, Chung FT, Lin TY, Wang CL, Guo YK, Yang CT.
    Target Oncol; 2019 Aug 06; 14(4):433-440. PubMed ID: 31346928
    [Abstract] [Full Text] [Related]

  • 20. Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer.
    Zhang W, Zhang Q, Che L, Xie Z, Cai X, Gong L, Li Z, Liu D, Liu S.
    BMC Cancer; 2022 Mar 21; 22(1):299. PubMed ID: 35313857
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.